An initial study indicated that inhibiting Beclin-1 accelerated the progression of premalignant lesions caused by agents like the hepatitis B virus, enhanced the emergence of spontaneous cancers in the lung, liver, and lymphomas, and promoted mammary hyperplasia (Liang et al., 1999). Here, BECN1 is linked to lymphoma.